ITRM20010464A1 - Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica. - Google Patents

Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.

Info

Publication number
ITRM20010464A1
ITRM20010464A1 IT2001RM000464A ITRM20010464A ITRM20010464A1 IT RM20010464 A1 ITRM20010464 A1 IT RM20010464A1 IT 2001RM000464 A IT2001RM000464 A IT 2001RM000464A IT RM20010464 A ITRM20010464 A IT RM20010464A IT RM20010464 A1 ITRM20010464 A1 IT RM20010464A1
Authority
IT
Italy
Prior art keywords
tumoral
antiangiogenic
pro
retinoid derivatives
apoptotic activities
Prior art date
Application number
IT2001RM000464A
Other languages
English (en)
Italian (it)
Inventor
Lucio Merlini
Sabrina Dallavalle
Sergio Penco
Giuseppe Giannini
Loredana Vesci
Claudio Pisano
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11455702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITRM20010464(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT2001RM000464A priority Critical patent/ITRM20010464A1/it
Publication of ITRM20010464A0 publication Critical patent/ITRM20010464A0/it
Priority to BR0211521-2A priority patent/BR0211521A/pt
Priority to KR1020047001546A priority patent/KR100888466B1/ko
Priority to CNB028150082A priority patent/CN1279014C/zh
Priority to AT02760553T priority patent/ATE492526T1/de
Priority to CA2454532A priority patent/CA2454532C/en
Priority to AU2002326144A priority patent/AU2002326144B2/en
Priority to MXPA04000877A priority patent/MXPA04000877A/es
Priority to EP02760553A priority patent/EP1412317B1/en
Priority to PL368412A priority patent/PL207530B1/pl
Priority to DK02760553.4T priority patent/DK1412317T3/da
Priority to US10/485,530 priority patent/US8101793B2/en
Priority to DE60238683T priority patent/DE60238683D1/de
Priority to PT02760553T priority patent/PT1412317E/pt
Priority to HU0401604A priority patent/HU229308B1/hu
Priority to ES02760553T priority patent/ES2358097T3/es
Priority to JP2003517002A priority patent/JP4463550B2/ja
Priority to HK05101240.1A priority patent/HK1068868B/xx
Priority to PCT/IT2002/000474 priority patent/WO2003011808A1/en
Publication of ITRM20010464A1 publication Critical patent/ITRM20010464A1/it
Priority to US11/765,737 priority patent/US7449495B2/en
Priority to CY20111100294T priority patent/CY1114535T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
IT2001RM000464A 2001-07-31 2001-07-31 Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica. ITRM20010464A1 (it)

Priority Applications (21)

Application Number Priority Date Filing Date Title
IT2001RM000464A ITRM20010464A1 (it) 2001-07-31 2001-07-31 Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
HK05101240.1A HK1068868B (en) 2001-07-31 2002-07-18 Retinoid derivatives with antiangiogenic, antitutmoral and proapoptotic activities
PCT/IT2002/000474 WO2003011808A1 (en) 2001-07-31 2002-07-18 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
PL368412A PL207530B1 (pl) 2001-07-31 2002-07-18 Związek, kompozycja farmaceutyczna, kombinacja i ich zastosowanie
DE60238683T DE60238683D1 (de) 2001-07-31 2002-07-18 Retinoid derivate mit antiangiogener, antitumor und proapoptotischer wirkung
CNB028150082A CN1279014C (zh) 2001-07-31 2002-07-18 具有抗血管生成、抗肿瘤和促凋亡活性的类维生素a衍生物
AT02760553T ATE492526T1 (de) 2001-07-31 2002-07-18 Retinoid derivate mit antiangiogener, antitumor und proapoptotischer wirkung
CA2454532A CA2454532C (en) 2001-07-31 2002-07-18 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
AU2002326144A AU2002326144B2 (en) 2001-07-31 2002-07-18 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
MXPA04000877A MXPA04000877A (es) 2001-07-31 2002-07-18 Derivados retinoides con actividades antiangiogenicas, antitumorales y proapoptoticas.
EP02760553A EP1412317B1 (en) 2001-07-31 2002-07-18 Retinoid derivatives with antiangiogenic, antitumor and proapoptotic activities
BR0211521-2A BR0211521A (pt) 2001-07-31 2002-07-18 Derivados de retinóide com atividades antiangiogênicas, antitumorais e pró-apoptóticas
DK02760553.4T DK1412317T3 (da) 2001-07-31 2002-07-18 Retinoidderivater med antiangiogenetisk-, antitumor og pro-apoptotisk virkning
US10/485,530 US8101793B2 (en) 2001-07-31 2002-07-18 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
KR1020047001546A KR100888466B1 (ko) 2001-07-31 2002-07-18 혈관형성 억제, 항 종양 및 전 세포사멸 활성을 갖는레티노이드 유도체
PT02760553T PT1412317E (pt) 2001-07-31 2002-07-18 Derivados retinóides com actividades anti-angiogénica, anti-tumoral e pró-apoptótica
HU0401604A HU229308B1 (en) 2001-07-31 2002-07-18 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
ES02760553T ES2358097T3 (es) 2001-07-31 2002-07-18 Derivados retinoides con actividades antiangiogénicas, antitumorales y proapoptóticas.
JP2003517002A JP4463550B2 (ja) 2001-07-31 2002-07-18 抗血管新生、抗腫瘍性およびアポトーシス促進性の活性を有するレチノイド誘導体
US11/765,737 US7449495B2 (en) 2001-07-31 2007-06-20 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
CY20111100294T CY1114535T1 (el) 2001-07-31 2011-03-16 Ρετινοειδη παραγωγα με αντιαγγειογονικες, αντιογκικες και προαποπτωτικες δραστικοτητες

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000464A ITRM20010464A1 (it) 2001-07-31 2001-07-31 Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.

Publications (2)

Publication Number Publication Date
ITRM20010464A0 ITRM20010464A0 (it) 2001-07-31
ITRM20010464A1 true ITRM20010464A1 (it) 2003-01-31

Family

ID=11455702

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001RM000464A ITRM20010464A1 (it) 2001-07-31 2001-07-31 Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.

Country Status (19)

Country Link
US (2) US8101793B2 (https=)
EP (1) EP1412317B1 (https=)
JP (1) JP4463550B2 (https=)
KR (1) KR100888466B1 (https=)
CN (1) CN1279014C (https=)
AT (1) ATE492526T1 (https=)
AU (1) AU2002326144B2 (https=)
BR (1) BR0211521A (https=)
CA (1) CA2454532C (https=)
CY (1) CY1114535T1 (https=)
DE (1) DE60238683D1 (https=)
DK (1) DK1412317T3 (https=)
ES (1) ES2358097T3 (https=)
HU (1) HU229308B1 (https=)
IT (1) ITRM20010464A1 (https=)
MX (1) MXPA04000877A (https=)
PL (1) PL207530B1 (https=)
PT (1) PT1412317E (https=)
WO (1) WO2003011808A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
EP1456165A1 (en) * 2001-11-30 2004-09-15 The Burnham Institute Induction of apoptosis in cancer cells
CA2471140A1 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
CA2598518C (en) 2005-02-22 2015-04-21 Ranbaxy Laboratories Limited 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
FR2884248B1 (fr) * 2005-04-08 2007-05-18 Galderma Res & Dev Nouveau procede de preparation de l'acide 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoique
JP5155148B2 (ja) * 2005-04-08 2013-02-27 ガルデルマ・リサーチ・アンド・デヴェロップメント ６−［３−（１−アダマンチル）−４−メトキシフェニル］−２−ナフトエ酸の合成方法
ITRM20050248A1 (it) * 2005-05-20 2006-11-21 Sigma Tau Ind Farmaceuti Uso acido adamantil metossidifenil propenoico per il trattamento di patologie cutanee.
JP5080462B2 (ja) 2005-06-28 2012-11-21 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ ビフェニルおよびナフチル−フェニルヒドロキサム酸誘導体
WO2007037188A1 (ja) * 2005-09-27 2007-04-05 Sapporo Medical University 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
WO2007071605A1 (en) * 2005-12-19 2007-06-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. The use of st1898 for the treatment of restenosis
JP5054006B2 (ja) * 2006-06-23 2012-10-24 ロート製薬株式会社 ヒアルロン酸産生促進能を有する組成物
US20100330200A1 (en) * 2006-12-22 2010-12-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combination of a retinoid and a platinum anticancer agent
WO2010000784A1 (en) * 2008-07-03 2010-01-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treatment of restenosis
TW201031402A (en) * 2008-12-24 2010-09-01 Sigma Tau Ind Farmaceuti New retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010106135A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use for the treatment of ovarian carcinoma
CN102892755A (zh) 2009-12-23 2013-01-23 韦恩州立大学 治疗性化合物
AU2012311640B2 (en) * 2011-09-19 2017-04-13 Alfasigma S.P.A. New thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments
JP5757602B2 (ja) * 2012-05-11 2015-07-29 国立大学法人金沢大学 不斉選択性の切り替えが可能なクロマトグラフィー用充填剤
CN104496839B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
WO2017053778A1 (en) 2015-09-25 2017-03-30 Fuchs Helen Burgwyn Antibacterial and antifungal compounds
AU2017208970A1 (en) 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
EP3301085A1 (en) * 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoid derivatives with antitumor activity
WO2018201074A1 (en) * 2017-04-27 2018-11-01 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
IT201900003343A1 (it) * 2019-03-07 2020-09-07 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
CN111956806B (zh) * 2020-09-03 2023-04-07 四川大学 一种药物载体、胶束、药剂及其制备方法和应用
IT202000029882A1 (it) * 2020-12-04 2022-06-04 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi
IT202000029906A1 (it) * 2020-12-04 2022-06-04 Special Product’S Line S P A Derivati fenolici per uso come antimicrobici, antibatterici, battericidi.
WO2022229017A1 (en) 2021-04-27 2022-11-03 Biogem S.C.A R.L. Adamantyl retinoid derivative with anticancer activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676052B1 (fr) * 1991-05-02 1994-04-29 Cird Galderma Nouveaux composes polycycliques aromatiques et leur utilisation en medecine humaine ou veterinaire et en cosmetique.
IL127946A0 (en) * 1996-07-08 2000-02-17 Cird Galderma Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
ITRM20010464A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
EP1456165A1 (en) * 2001-11-30 2004-09-15 The Burnham Institute Induction of apoptosis in cancer cells

Also Published As

Publication number Publication date
JP2004536879A (ja) 2004-12-09
CY1114535T1 (el) 2016-10-05
JP4463550B2 (ja) 2010-05-19
AU2002326144B2 (en) 2008-04-10
ATE492526T1 (de) 2011-01-15
US20040235757A1 (en) 2004-11-25
ES2358097T3 (es) 2011-05-05
MXPA04000877A (es) 2004-06-03
US8101793B2 (en) 2012-01-24
US20080021088A1 (en) 2008-01-24
CA2454532C (en) 2011-01-25
EP1412317B1 (en) 2010-12-22
DE60238683D1 (de) 2011-02-03
PT1412317E (pt) 2011-03-21
HK1068868A1 (en) 2005-05-06
CN1279014C (zh) 2006-10-11
US7449495B2 (en) 2008-11-11
PL368412A1 (en) 2005-03-21
WO2003011808A1 (en) 2003-02-13
PL207530B1 (pl) 2010-12-31
CA2454532A1 (en) 2003-02-13
CN1537094A (zh) 2004-10-13
HU229308B1 (en) 2013-10-28
HUP0401604A2 (hu) 2004-12-28
HUP0401604A3 (en) 2006-01-30
KR100888466B1 (ko) 2009-03-12
KR20040028968A (ko) 2004-04-03
BR0211521A (pt) 2004-09-14
ITRM20010464A0 (it) 2001-07-31
EP1412317A1 (en) 2004-04-28
DK1412317T3 (da) 2011-03-28

Similar Documents

Publication Publication Date Title
ITRM20010464A1 (it) Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
HRP20080664A2 (hr) Supstituirani piridinski herbicidi
CY1106076T1 (el) Παραγωγα γλυκοπυρανοσυλοξυβενζυλο βενζολιου και ιατρικες συνθεσεις που πepιεχουν τα ιδια
HUS2000011I1 (hu) A 2,4-pirimidin-diamin vegyületek elõgyógyszerei és alkalmazásuk
CY1111867T1 (el) Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
PA8527001A1 (es) Poliarilcarboxamidas utiles como agentes reductores de lipidos
EA199800645A1 (ru) Фунгицидные 2-метоксибензофеноны
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
DK1200418T3 (da) Nematodicide trifluorbutener
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
BR0307924A (pt) N-aril-2-oxazolidinona-5-carboxamidas e seus derivados
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
ES2187261B2 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
DK1643984T3 (da) Anvendelse af parthenolidderivater som antileukæmiske og cytotoksske midler
ATE259813T1 (de) Triazolopyrimidinderivate
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
DK1204659T3 (da) Serotonerge benzofuraner
NO20063293L (no) Farmasoytiske forbindelser
BR0206922A (pt) Compostos orgânicos
SV2004001441A (es) Compuestos de isocromano ref. x-14205
DE69915688D1 (de) Benzonaphtyridin-1,8 derivate
ITMI20030590A1 (it) Macchina conificatrice comprendente due o piu' tavole traslanti abbinate.
ECSP045147A (es) "2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su empleo"